SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Director/PDMR Shareholding

2 Apr 2020 13:36

RNS Number : 6127I
Rentokil Initial PLC
02 April 2020
 

Rentokil Initial plc

2 April 2020

 

Notification of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

Rentokil Initial plc (the "Company") hereby announces that the award granted under the Rentokil Initial plc Performance Share Plan (PSP) in March 2017 for John Myers (a person discharging managerial responsibility) of 153,277 shares has been released with 56,848 of these shares subsequently being sold at a share price of £3.6216 to cover his tax and social security liability.

The Company further announces that Chris Hunt (a person discharging managerial responsibility) has today purchased 2,708 ordinary shares in the Company at a price of £3.67 per share.

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

John Myers

2

 

Reason for the notification

 

a)

 

Position/status

 

Managing Director, North America

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Rentokil Initial plc

b)

 

LEI

 

549300VN4WV7Z6T14K68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 1p each

 

 

ISIN: GB00B082RF11

 

b)

 

Nature of the transaction

 

 

Release of awards made under the 2017 Performance Share Plan (PSP)

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

 

Nil consideration

 

153,277

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

153,277 shares

 

-

 

e)

 

Date of the transaction

 

31 March 2020

f)

 

Place of the transaction

 

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

John Myers

2

 

Reason for the notification

 

a)

 

Position/status

 

Managing Director, North America

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Rentokil Initial plc

b)

 

LEI

 

549300VN4WV7Z6T14K68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 1p each

 

 

ISIN: GB00B082RF11

 

b)

 

Nature of the transaction

 

 

Sale of shares to cover the tax and social security liability arising following the release of an award made under the 2017 Performance Share Plan (PSP).

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

 

£3.6216

 

56,848

d)

 

Aggregated information

 

- Aggregated volume

 

- Aggregated price

 

- Total

 

 

 

56,848 shares

 

£3.6216

 

£205,880.72

e)

 

Date of the transaction

 

1 April 2020

f)

 

Place of the transaction

 

London Stock Exchange (XLON)

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

Chris Hunt

 

2

 

Reason for the notification

 

a)

 

Position/status

 

Group M&A Director (PDMR)

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Rentokil Initial plc

b)

 

LEI

 

549300VN4WV7Z6T14K68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 1p each

 

 

ISIN: GB00B082RF11

b)

 

Nature of the transaction

 

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£3.67

2,708

d)

 

Aggregated information

 

- Aggregated volume

 

- Aggregated price

 

- Total

 

 

 

2,708

 

£3.67

 

£9,938.36

e)

 

Date of the transaction

 

2 April 2020

f)

 

Place of the transaction

 

London Stock Exchange (XLON)

 

Enquiries:

 

Daragh Fagan, Company Secretary Rentokil Initial plc 01276 607444

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBDGDSXXGDGGD
Date   Source Headline
28th Jul 20253:00 pmRNSHolding(s) in Company
10th Jul 202511:00 amRNSHolding(s) in Company
1st Jul 202510:25 amRNSTotal Voting Rights
10th Jun 202510:05 amRNSAdditional Listing
3rd Jun 20254:00 pmRNSDirector/PDMR Shareholding
28th May 20257:00 amRNSSale of France Workwear
19th May 20252:30 pmRNSDirector/PDMR Shareholding
7th May 20254:15 pmRNSResult of AGM
7th May 20257:01 amRNSDirectorate Change: Appointment of NEDs
7th May 20257:00 amRNSDirectorate Change: Chief Executive to retire
28th Apr 20252:30 pmRNSIssue of Debt
17th Apr 20252:20 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSQ1 Trading Update
9th Apr 202510:25 amRNSHolding(s) in Company
1st Apr 20252:15 pmRNSNotice of Q1 Trading Update and Management Call
1st Apr 202510:25 amRNSBlock listing Interim Review
27th Mar 202510:25 amRNSDirector/PDMR Shareholding
26th Mar 202510:30 amRNSAnnual Financial Report
14th Mar 202510:00 amRNSDirector/PDMR Shareholding
6th Mar 20257:00 amRNSFinal Results
28th Jan 20257:00 amRNSTrading Update (unaudited)
14th Jan 202511:15 amRNSHolding(s) in Company
13th Jan 202511:15 amRNSHolding(s) in Company
13th Dec 20249:30 amRNSDirector/PDMR Shareholding
25th Nov 20247:00 amRNSDirectorate Change
12th Nov 202410:30 amRNSHolding(s) in Company
8th Nov 202410:30 amRNSHolding(s) in Company
17th Oct 20247:00 amRNSQ3 Trading Update
1st Oct 20242:00 pmRNSBlock listing Interim Review
25th Sep 20247:00 amRNSAppointment of Non-Executive Director
19th Sep 202410:30 amRNSDirector/PDMR Shareholding
11th Sep 20247:00 amRNSTrading Update
10th Sep 202410:30 amRNSHolding(s) in Company
5th Sep 202411:08 amRNSHolding(s) in Company
25th Jul 20247:00 amRNS2024 Interim Results
10th Jul 20244:35 pmRNSHolding(s) in Company
26th Jun 20245:12 pmRNSDirector/PDMR Shareholding
26th Jun 202411:08 amRNSHolding(s) in Company
17th May 20243:30 pmRNSDirector/PDMR Shareholding
8th May 20242:00 pmRNSResult of AGM
29th Apr 20243:00 pmRNSHolding(s) in Company
23rd Apr 20249:30 amRNSHolding(s) in Company
18th Apr 20247:00 amRNSQ1 Trading Update
2nd Apr 20241:28 pmRNSBlock listing Interim Review
2nd Apr 202412:17 pmRNSTotal Voting Rights
27th Mar 202410:23 amRNSAnnual Financial Report
19th Mar 20242:05 pmRNSAdditional Listing
14th Mar 202410:19 amRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSFinal Results
1st Dec 20237:00 amRNSNorth American Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.